[Non-metastatic advanced non-small cell lung carcinoma: systemic high-dose brachytherapy following curative external radiotherapy].
OBJECTIVE
To analyse retrospectively the local control, overall survival and immediate and long-term tolerance after a radiotherapy delivered with a curative intent systematically including a high-dose rate brachytherapy.


METHODS
From January 1993 to January 1995, 50 patients (45 males-five females, median age: 61) with non-small cell lung cancers, inoperable for tumour reasons, non-metastatic, were included in the protocol. Following external radiotherapy (55-65 Gy conventional fractionation), all the patients received high-dose rate brachytherapy delivering 14 to 24 Gy using fractions of 7 Gy.


RESULTS
Immediate tolerance was good. Two months after the end of the treatment, five patients suffered from massive haemorrhages and three others experienced a mucosal necrosis (two tracheal sites). Tumour response was observed endoscopically in 88% of the cases (38/50) and was complete in 38%. Median survival of complete responders was 15 months. In the mean follow-up period of 24 months, five patients were still alive with no evidence of disease (median survival: 30 months). Most of the patients died from distant metastases (33/50: 66%).


CONCLUSIONS
Systematic use of endoluminal high-dose rate brachytherapy in addition to external radiotherapy did not improve survival. The gain in the local control rate was counteracted by an increase in haemorrhages and mucosal necroses. Improving techniques and dosimetry, and combining different methods which have proved their efficiency, should result in improvements in survival. Quality of life would be part of the analysed parameters in any future study.
Nguyen
T D
TD
Institut Jean-Godinot, centre régional de lutte contre le cancer de Reims, France.
Picavet
B
B
Mallet
F
F
Prevost
A
A
Berthiot
G
G
Loirette
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome